SGLT2 inhibitors
News/ News/ R&D/ Top stories
Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart failure
Phil Taylor
AstraZeneca, Boehringer Ingelheim, Eli Lilly, Farxiga, heart failure, Jardiance, SGLT2 inhibitors
0 Comment
Janssen taps wearable tech in Invokana heart failure trial
Phil Taylor
digital, heart failure, Invokana, Janssen, Johnson & Johnson, SGLT2 inhibitors, wearable
0 Comment
Market Access/ News/ News/ News/ R&D/ Top stories
Boehringer, Lilly start acute heart failure trial with Jardiance
Phil Taylor
Boehringer Ingelheim, Eli Lilly, heart failure, Jardiance, SGLT2 inhibitors
0 Comment
AZ’s Forxiga gets heart claim data on its EU label
Phil Taylor
AstraZeneca, cardiovascular outcomes, Forxiga, SGLT2 inhibitors, Type 2 diabetes
0 Comment
FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failure
Phil Taylor
Boehringer Ingelheim, cardiovascular outcomes, Eli Lilly, heart failure, SGLT2 inhibitors
0 Comment
Diabetes/ Diabetes/ News/ News/ Patients
FDA warns of genital gangrene risk with diabetes drug class
Piotr Wnuk
Diabetes, FDA warning, SGLT2 inhibitors
0 Comment
AZ’s diabetes combination Qtern approved in Europe
Andrew McConaghie
AstraZeneca, Diabetes, SGLT2 inhibitors
0 Comment